0-9
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1001 | 14-3-3 |
| 1002 | 14-3-3 sigma |
| 1003 | 14-3-3 beta |
| 1004 | 2-CdA |
| 1005 | 2-hydroxyadenine |
| 1006 | 3-D culture |
| 1007 | 4-1BBL |
| 1008 | 4-HNE |
| 1009 | 4NQO |
| 1010 | 5-FU |
| 1011 | 5-Lipoxygenase |
| 1012 | 8-hydroxydeoxyguanosine |
| 1013 | 8-OH-Gua |
A
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1014 | AAV vector |
| 1015 | ABC transporter |
| 1016 | ABCG2 |
| 1017 | ACF |
| 1018 | Acridone alkaloid |
| 1019 | Acrylamide |
| 1020 | Actin |
| 1021 | Acyclic retinoid |
| 1022 | ADAM17 |
| 1023 | Adaptor molecule |
| 1024 | Adenoma / adenocarcinoma |
| 1025 | Adenomatous polyposis coli |
| 1026 | Adenovirus |
| 1027 | Adenovirus vector |
| 1028 | ADFP |
| 1029 | adipocyte |
| 1030 | Adjuvant therapy |
| 1031 | ADPribosylation |
| 1032 | Adrenomedullin |
| 1033 | Aerosol therapy |
| 1034 | agarose 2-DE |
| 1035 | age at risk |
| 1036 | Aging |
| 1037 | Agricus blazei |
| 1038 | Ah receptor |
| 1039 | AHCC |
| 1040 | AIM-1 |
| 1041 | Akt |
| 1042 | Alcohol |
| 1043 | Allogeneic transplantation |
| 1044 | All-trans retinoic acid |
| 1045 | alpha 1 acid glycoprotein |
| 1046 | Alpha fetoprotein |
| 1047 | Alpha4 |
| 1048 | Alpha-GalCer |
| 1049 | Alpinia |
| 1050 | ALT |
| 1051 | Alternative splicing |
| 1052 | alternative therapies |
| 1053 | AMF |
| 1054 | Aminopeptidase N |
| 1055 | Aminophenylnorharman |
| 1056 | AML |
| 1057 | AML1 |
| 1058 | AMP-activated protein kinase |
| 1059 | ampulla of Vater carcinoma |
| 1060 | Anchorage dependent growth |
| 1061 | Androgen |
| 1062 | androgen receptor |
| 1063 | Aneuploidy |
| 1064 | Angiogenesis |
| 1065 | Angiogenesis inhibition |
| 1066 | Angiogenin |
| 1067 | Angiopoietin |
| 1068 | angiotensin |
| 1069 | Animal model |
| 1070 | Annexin |
| 1071 | anserine |
| 1072 | anthracycline |
| 1073 | Anti cancer drug |
| 1074 | Anti metabolight |
| 1075 | Antibody |
| 1076 | Antioxidants |
| 1077 | Antisense |
| 1078 | Antitumor activity |
| 1079 | antitumor CTL |
| 1080 | Anti-tumor promoter |
| 1081 | Antrodia camphorata |
| 1082 | AP-1 |
| 1083 | AP-2 |
| 1084 | Apaf1 |
| 1085 | APC |
| 1086 | Apoptosis |
| 1087 | Apoptosis related gene |
| 1088 | Arctiin |
| 1089 | ARF |
| 1090 | Arf6 |
| 1091 | ARK5 |
| 1092 | array CGH |
| 1093 | Arsenic |
| 1094 | Asbestos |
| 1095 | Ascorbic acid |
| 1096 | ASK1 |
| 1097 | Astrocytoma |
| 1098 | ASY |
| 1099 | Atelocollagen |
| 1100 | ATL |
| 1101 | ATL mouse model |
| 1102 | ATM |
| 1103 | AU-rich |
| 1104 | Aurora kinase |
| 1105 | autophagy |
| 1106 | Auxin |
| 1107 | Azoxymethane |
B
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1108 | B lymphocyte |
| 1109 | bacteria |
| 1110 | Bax |
| 1111 | B-cell lymphoma |
| 1112 | BCG |
| 1113 | BCG-CWS |
| 1114 | Bcl-2 |
| 1115 | Bcl-x |
| 1116 | Bcr-Abl |
| 1117 | BCRP |
| 1118 | Beta catenin |
| 1119 | beta-transducin repeats-containing protein |
| 1120 | Bhemophagocytic syndrome |
| 1121 | BHP |
| 1122 | Bile |
| 1123 | Bile acid |
| 1124 | Bile acid conjugate |
| 1125 | Biliary tract carcinoma |
| 1126 | bilirubin |
| 1127 | Bim |
| 1128 | Bioinformatics |
| 1129 | biomarker |
| 1130 | biopsy |
| 1131 | Biostatistics |
| 1132 | Birth cohort |
| 1133 | bispecific diabody |
| 1134 | Bisphosphonate |
| 1135 | bladder |
| 1136 | Bladder cancer |
| 1137 | Blood flow |
| 1138 | Bloom syndrome |
| 1139 | BMI-1 |
| 1140 | BMP |
| 1141 | BMP-2 |
| 1142 | BNCT |
| 1143 | Body mass index |
| 1144 | bone marker |
| 1145 | Bone marrow |
| 1146 | Bone marrow transplantation |
| 1147 | Bone metastases |
| 1148 | BORIS |
| 1149 | BRAF |
| 1150 | Brain metastasis |
| 1151 | Brain tumor |
| 1152 | BRCA1/2 |
| 1153 | Breast cancer |
| 1154 | BRM |
| 1155 | Burkitt Lymphoma |
| 1156 | Bystander effect |
C
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1157 | CA125 |
| 1158 | C-Abl |
| 1159 | Cachexia |
| 1160 | Cadherin |
| 1161 | Caffeine |
| 1162 | CagA |
| 1163 | calcium channel |
| 1164 | calcium channel blockers |
| 1165 | Calponin |
| 1166 | camptothecin |
| 1167 | Cancer Antigen |
| 1168 | cancer control |
| 1169 | Cancer genetics |
| 1170 | Cancer mortality |
| 1171 | Cancer prevention |
| 1172 | Cancer registry |
| 1173 | Cancer risk assessment |
| 1174 | cancer stem cell |
| 1175 | Cancer vaccine |
| 1176 | Cap43 |
| 1177 | CAR |
| 1178 | Carbohydrate antigen |
| 1179 | Carbon ion therapy |
| 1180 | Carcinogen |
| 1181 | Carcinogenesis |
| 1182 | carcinosarcoma |
| 1183 | Case-control study |
| 1184 | Caspase |
| 1185 | catechin |
| 1186 | Cathepsin |
| 1187 | Cathepsin E |
| 1188 | Caveolin |
| 1189 | Cbl |
| 1190 | CCL3L1 |
| 1191 | CCR4 |
| 1192 | CD10 |
| 1193 | CD155 |
| 1194 | CD20 |
| 1195 | CD30 |
| 1196 | CD40 ligand |
| 1197 | CD44 |
| 1198 | CD4CD152 T cells |
| 1199 | CD55 |
| 1200 | CD56 |
| 1201 | CD62L |
| 1202 | CD8 |
| 1203 | CD82 |
| 1204 | CD9 |
| 1205 | CD98 |
| 1206 | CDA-II |
| 1207 | Cdc2 |
| 1208 | CDC25 |
| 1209 | Cdc25B |
| 1210 | cdc6 |
| 1211 | CDH17 |
| 1212 | Cdk |
| 1213 | cDNA microarray |
| 1214 | Cdx |
| 1215 | CEA |
| 1216 | Cell adhesion |
| 1217 | cell adhesion molecules |
| 1218 | Cell cycle |
| 1219 | Cell cycle arrest |
| 1220 | Cell cycle checkpoint |
| 1221 | Cell death |
| 1222 | Cell density |
| 1223 | Cell differentiation |
| 1224 | Cell line |
| 1225 | Cell migration /motility |
| 1226 | Cell polarity |
| 1227 | cell survival gene |
| 1228 | Cell therapy |
| 1229 | centromere protein |
| 1230 | Centrosome |
| 1231 | Cervical cancer |
| 1232 | CGH |
| 1233 | CGH-array |
| 1234 | Chaperone |
| 1235 | Chemokine |
| 1236 | chemokine receptor |
| 1237 | Chemoprevention |
| 1238 | chemoradiotherapy |
| 1239 | Chemosensitivity |
| 1240 | Chemosensitivity prediction |
| 1241 | Chemotherapy |
| 1242 | chemotherapy-induced alopecia |
| 1243 | CHFR |
| 1244 | CHK2 |
| 1245 | Chloronitrobenzene |
| 1246 | Cholangiocarcinoma |
| 1247 | Cholesterol |
| 1248 | chromatin immunoprecipitation |
| 1249 | Chromatin remodeling |
| 1250 | Chromosomal instability |
| 1251 | Chromosome |
| 1252 | Chromosome 12 |
| 1253 | chromosome 3q |
| 1254 | Chromosome aberration |
| 1255 | Chromosome translocation |
| 1256 | Chymase |
| 1257 | Cimetidine |
| 1258 | Cisplatin |
| 1259 | c-jun |
| 1260 | C-kit |
| 1261 | Cks1 |
| 1262 | Claudin |
| 1263 | Clinical trial |
| 1264 | CLL |
| 1265 | Clock |
| 1266 | C-MET |
| 1267 | CML |
| 1268 | C-Myc |
| 1269 | cofactor |
| 1270 | cofilin |
| 1271 | Cohort study |
| 1272 | colon cancer |
| 1273 | Colon carcinogenesis |
| 1274 | colonic cancer |
| 1275 | Colorectal adenoma |
| 1276 | Colorectal cancer |
| 1277 | Combination effect |
| 1278 | comparative genomic hybridization |
| 1279 | Computer simulation |
| 1280 | Conditional gene targeting |
| 1281 | Confocal endoscopy |
| 1282 | Connexin |
| 1283 | core competence |
| 1284 | cortactin |
| 1285 | Cost analysis |
| 1286 | COX |
| 1287 | COX-2 |
| 1288 | CpG DNA |
| 1289 | CpG methylation |
| 1290 | CpG oligonucleotide |
| 1291 | CPT-11 |
| 1292 | Crk |
| 1293 | cryotherapy |
| 1294 | CT antigen |
| 1295 | CTL |
| 1296 | Curcumin |
| 1297 | CXCR4 |
| 1298 | Cyclin |
| 1299 | cyclin A |
| 1300 | Cyclophosphamide |
| 1301 | CYP |
| 1302 | Cyst formation |
| 1303 | cytarabine |
| 1304 | Cytodiagnosis |
| 1305 | Cytokeratin |
| 1306 | Cytokine |
| 1307 | Cytokinesis |
| 1308 | cytoplasmic retention |
| 1309 | Cytoskeleton |
| 1310 | Cytotoxic activity |
D
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1311 | D40 |
| 1312 | DAL-1 |
| 1313 | DCM |
| 1314 | DDS |
| 1315 | Dedifferentiation |
| 1316 | demethylation |
| 1317 | DEN |
| 1318 | Dendritic cell |
| 1319 | Dendritic cell therapy |
| 1320 | depression |
| 1321 | developing cancer |
| 1322 | DHA |
| 1323 | Diabetes mellitus |
| 1324 | Diagnosis |
| 1325 | dietary fat |
| 1326 | differentiation |
| 1327 | Dihydropyrimidine Dehydrogenase |
| 1328 | dihydrotestosterone |
| 1329 | DLG |
| 1330 | DMBA |
| 1331 | DMN |
| 1332 | DNA adduct |
| 1333 | DNA chip |
| 1334 | DNA computing |
| 1335 | DNA damage |
| 1336 | DNA fragmentation |
| 1337 | DNA methylation |
| 1338 | DNA methyltransferase-1 |
| 1339 | DNA microarray |
| 1340 | DNA mismatch repair |
| 1341 | DNA polymerase |
| 1342 | DNA repair |
| 1343 | DNA Replication |
| 1344 | DNA synthesis |
| 1345 | DNA tumor viruses |
| 1346 | DNA vaccine |
| 1347 | DNA-PK |
| 1348 | Docetaxel |
| 1349 | dohevanil |
| 1350 | Dok family protein |
| 1351 | Dominant negative |
| 1352 | double strand break |
| 1353 | Doxorubicin |
| 1354 | Drug discovery |
| 1355 | Drug resistance |
| 1356 | Drug response |
| 1357 | dysadherin |
E
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1358 | E2F |
| 1359 | E7070 |
| 1360 | E7107 |
| 1361 | EBV |
| 1362 | E-cadherin |
| 1363 | Economic evaluation |
| 1364 | education |
| 1365 | education and board |
| 1366 | EGCG |
| 1367 | EGF |
| 1368 | EGF receptor |
| 1369 | Ehrlich tumor cell |
| 1370 | EID |
| 1371 | electronic magnetic field |
| 1372 | Electroporation |
| 1373 | ELISA |
| 1374 | Embryonic stem cell |
| 1375 | EMMPRIN |
| 1376 | Emodin |
| 1377 | EMT |
| 1378 | Endocrine disruptor |
| 1379 | Endocytosis |
| 1380 | Endometrial cancer |
| 1381 | Endoplasmic reticulum |
| 1382 | Endothelial cell |
| 1383 | Endothelial progenitor cell |
| 1384 | Endothelin |
| 1385 | enterolactone |
| 1386 | Eph/Eph receptor |
| 1387 | Epidemiology |
| 1388 | Epigenetics |
| 1389 | Epithelial cells |
| 1390 | Epithelial Mesenchymal Transition |
| 1391 | ErbB-2/ HER2 /Neu |
| 1392 | Erc gene |
| 1393 | ERK |
| 1394 | ERM proteins |
| 1395 | Ertyhroid progenitor |
| 1396 | Esophageal cancer |
| 1397 | Estrogen |
| 1398 | Estrogen receptor |
| 1399 | ethics education |
| 1400 | Ets |
| 1401 | evaluation of toxicity |
| 1402 | EVI1 |
| 1403 | Ewing sarcoma |
| 1404 | EWS-Fli1 |
| 1405 | Exercise |
| 1406 | exercise training |
| 1407 | EZH2 |
F
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1408 | FAK |
| 1409 | Familial cancer |
| 1410 | Family history |
| 1411 | family intervention |
| 1412 | Fanconi Anemia |
| 1413 | Fas |
| 1414 | Fatty acid |
| 1415 | Fatty acid ester |
| 1416 | F-box protein |
| 1417 | fentanyl transdermal patch |
| 1418 | FGF |
| 1419 | FHIT |
| 1420 | Fibronectin |
| 1421 | FISH |
| 1422 | FLIP |
| 1423 | FLT |
| 1424 | Flt3Ligand |
| 1425 | Fludarabine |
| 1426 | Fluidic Card System |
| 1427 | focal adhesion kinase |
| 1428 | FR901228 |
| 1429 | Fragile site |
| 1430 | frame-shift mutation |
| 1431 | Free radical |
| 1432 | FRET |
| 1433 | Fucoidan |
| 1434 | Fucosylated glycoforms |
| 1435 | Fucosyltransferase |
| 1436 | Fusion |
G
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1437 | G protein |
| 1438 | G1 arrest |
| 1439 | Gadd153 |
| 1440 | GADD45 |
| 1441 | galectin |
| 1442 | galectin-3 |
| 1443 | Gallbladder cancer |
| 1444 | gamma delta T cell |
| 1445 | Ganglioside |
| 1446 | Ganoderma lucidum AF |
| 1447 | Gap junction |
| 1448 | Gastric cancer |
| 1449 | Gastric carcinogenesis |
| 1450 | Gastrointestinal cancer |
| 1451 | Gastrointestinal stromal tumor |
| 1452 | GATA |
| 1453 | G-CSF |
| 1454 | GD3 |
| 1455 | GDNF |
| 1456 | GEF |
| 1457 | gefitinib |
| 1458 | Gelsolin |
| 1459 | Gemcitabine |
| 1460 | Gene amplification |
| 1461 | Gene delivery |
| 1462 | Gene expression |
| 1463 | Gene regulation |
| 1464 | Gene therapy |
| 1465 | Genetic alteration |
| 1466 | Genetic diagnosis |
| 1467 | Genetic factor |
| 1468 | Genistein |
| 1469 | Genome |
| 1470 | genome imprinting |
| 1471 | Genomic instability |
| 1472 | genomics |
| 1473 | genotoxicity test |
| 1474 | Geographical epidemiology |
| 1475 | germ cell tumor |
| 1476 | GFPmice |
| 1477 | Gli1 |
| 1478 | Glioblastoma |
| 1479 | Glioma |
| 1480 | Glivec |
| 1481 | Glucose deprivation |
| 1482 | Glutathione |
| 1483 | Glutathione S-transferase |
| 1484 | Glycidol |
| 1485 | Glycogen synthase kinase-3 |
| 1486 | Glycolysis |
| 1487 | Glycosilation |
| 1488 | glycosylation |
| 1489 | Glycosyltransferase |
| 1490 | Glypican3 |
| 1491 | GnT-V |
| 1492 | Green fluorescent protein |
| 1493 | Green tea |
| 1494 | Growth factor |
| 1495 | GSH |
| 1496 | Gynecologic cancer |
H
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1497 | H19 |
| 1498 | H2AX |
| 1499 | H3K9 methylation |
| 1500 | HAI-1 |
| 1501 | HAI-2 |
| 1502 | HB-EGF |
| 1503 | HBV |
| 1504 | HCV |
| 1505 | HDAC |
| 1506 | HDAC inhibitor |
| 1507 | HDGF |
| 1508 | Head and neck cancer |
| 1509 | Heat shock protein |
| 1510 | Heavy ion |
| 1511 | Hedgehog |
| 1512 | Helicobacter pylori |
| 1513 | Hematological malignancy |
| 1514 | hematopoietic chimerism |
| 1515 | Hematopoietic stem cell |
| 1516 | Heparan sulfate |
| 1517 | Heparanase |
| 1518 | Hepatoblastoma |
| 1519 | Hepatocarcinogenesis |
| 1520 | Hepatocellular carcinoma |
| 1521 | hepatocyte |
| 1522 | HER2 |
| 1523 | Herceptin |
| 1524 | Herpes virus |
| 1525 | Heterochromatin |
| 1526 | Heterocyclic amine |
| 1527 | HGF |
| 1528 | HGF activator |
| 1529 | HIF-1 |
| 1530 | Histone acetylation |
| 1531 | Histone modification |
| 1532 | HL60 |
| 1533 | HLA |
| 1534 | HLH transcription factor |
| 1535 | HMG-CoA reductase inhibitor |
| 1536 | HMLH1 |
| 1537 | HNPCC |
| 1538 | HnRNP |
| 1539 | Homeobox gene |
| 1540 | homeostatic proliferation |
| 1541 | Homologous recombination |
| 1542 | Homozygous deletion |
| 1543 | Hormonal therapy |
| 1544 | HPV |
| 1545 | hTERT |
| 1546 | HTLV-1 |
| 1547 | Human urine sample |
| 1548 | Humanized antibody |
| 1549 | H-warts |
| 1550 | Hyaluronan |
| 1551 | hypercoagulation |
| 1552 | Hyperplasia |
| 1553 | Hyperthermia |
| 1554 | Hypoxia |
I
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1555 | IAP |
| 1556 | ICAM-1 |
| 1557 | Id |
| 1558 | IFN |
| 1559 | IgE |
| 1560 | IGF |
| 1561 | IGF-1 |
| 1562 | IGFBP-3 |
| 1563 | IGF-I receptor |
| 1564 | Ikaros |
| 1565 | IKK |
| 1566 | IL-1 beta |
| 1567 | IL-10 |
| 1568 | IL-10 cytokine family |
| 1569 | IL-12 |
| 1570 | IL-17 |
| 1571 | IL-18 |
| 1572 | IL-2 |
| 1573 | IL-21 |
| 1574 | IL-23 |
| 1575 | IL-27 |
| 1576 | IL-4 |
| 1577 | IL-6 |
| 1578 | ILK |
| 1579 | imaging |
| 1580 | Immortalization |
| 1581 | Immune cell therapy |
| 1582 | Immune response |
| 1583 | Immune suppression |
| 1584 | Immunohistochemistry |
| 1585 | Immunotherapy |
| 1586 | Immunotoxin |
| 1587 | imprinting |
| 1588 | IMRT |
| 1589 | in vivo imaging |
| 1590 | individualized treatment |
| 1591 | Indole-3-carbinol |
| 1592 | Inflammation |
| 1593 | ING |
| 1594 | ING1 |
| 1595 | inhibitor |
| 1596 | Initiation |
| 1597 | INOS |
| 1598 | Insertional mutagenesis |
| 1599 | insulin |
| 1600 | Integrin |
| 1601 | Interferon |
| 1602 | intestinal immune system |
| 1603 | Intestinal metaplasia |
| 1604 | Invasion |
| 1605 | invasive ductal carcinoma |
| 1606 | IP3R |
| 1607 | IQ |
| 1608 | IQGAP1 |
| 1609 | IRES |
| 1610 | Iressa |
| 1611 | Irinotecan |
| 1612 | ISH |
| 1613 | Isothiocyanate derivatives |
J
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1614 | Jab1 |
| 1615 | JNK |
K
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1616 | Kampo medicine |
| 1617 | KDR Flk 1 |
| 1618 | kigamicin |
| 1619 | Kinase |
| 1620 | knockin mouse |
| 1621 | Kojic acid |
| 1622 | K-ras |
| 1623 | Ku70 |
L
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1624 | L1 adhesion molecule |
| 1625 | Lactobacillus casei |
| 1626 | Lactobacillus rhamnosus |
| 1627 | Lactoferrin |
| 1628 | LAK |
| 1629 | Laminin |
| 1630 | Laparoscopic surgery |
| 1631 | Laser Capture Microdissection |
| 1632 | LEC rat |
| 1633 | Lectin |
| 1634 | leucovorin |
| 1635 | Leukemia |
| 1636 | Leukemogenesis |
| 1637 | Life-style |
| 1638 | LightCycler |
| 1639 | LIM kinase |
| 1640 | linoleic acid |
| 1641 | Liposome |
| 1642 | Liver |
| 1643 | Liver carcinogenesis |
| 1644 | Liver cirrhosis |
| 1645 | Liver metastasis |
| 1646 | Livin |
| 1647 | LMP1 |
| 1648 | LMP2A |
| 1649 | L-myc |
| 1650 | LNCaP |
| 1651 | LOH |
| 1652 | LRP |
| 1653 | L-Tryptophan |
| 1654 | lung |
| 1655 | lung adenocarcinoma |
| 1656 | Lung cancer |
| 1657 | Lung carcinogenesis |
| 1658 | Lung Metastasis |
| 1659 | Lymph node metastasis |
| 1660 | lymphangiogenesis |
| 1661 | lymphangioleiomyomatosis |
| 1662 | lymphoma |
| 1663 | Lymphomagenesis |
| 1664 | Lymphoproliferation |
| 1665 | Lymphoproliferative disorders |
M
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1666 | Macroarray |
| 1667 | Macrophage |
| 1668 | MAGE |
| 1669 | magnifying endoscopy |
| 1670 | Malignant fibrous histiocytoma |
| 1671 | Malignant lymphoma |
| 1672 | malignant triton tumor |
| 1673 | MALT lymphoma |
| 1674 | Mammary tumor |
| 1675 | MAPK |
| 1676 | Marker |
| 1677 | Maspin |
| 1678 | Mass Spectrometry |
| 1679 | Matrilysin |
| 1680 | maxillar carcinoma |
| 1681 | MBD4 |
| 1682 | MCC465 |
| 1683 | MDM2 |
| 1684 | MDR |
| 1685 | MDR1 |
| 1686 | medical exposure |
| 1687 | medical oncologist |
| 1688 | MeIQx |
| 1689 | Mel18 |
| 1690 | Melanocyte |
| 1691 | Melanoma |
| 1692 | MEN |
| 1693 | Menin |
| 1694 | Mesenchymal Stem Cell |
| 1695 | Mesothelioma |
| 1696 | Metabolic activation |
| 1697 | Metalloprotease |
| 1698 | metallothionein |
| 1699 | Metaplasia |
| 1700 | Metastasis |
| 1701 | Metastasis suppressor gene |
| 1702 | methionine depletion |
| 1703 | Methotrexate |
| 1704 | Methylation |
| 1705 | MGMT |
| 1706 | Mi transcription factor |
| 1707 | Microarray |
| 1708 | microcystin |
| 1709 | microenvironment |
| 1710 | Micrometastasis |
| 1711 | microRNA |
| 1712 | Microsatellite instability |
| 1713 | Microtubule-associated protein |
| 1714 | Microtubule-Depolymerizing Agents |
| 1715 | Mig-6 |
| 1716 | Migrant study |
| 1717 | migration |
| 1718 | Min mouse |
| 1719 | Minisatellite binding protein |
| 1720 | Minor histocompatibility antigen |
| 1721 | Mismatch repair |
| 1722 | Mitochondria |
| 1723 | mitomycin C |
| 1724 | Mitosis |
| 1725 | Mitotic catastrophe |
| 1726 | MKL1 |
| 1727 | MKP |
| 1728 | MLL |
| 1729 | MLPA |
| 1730 | MMP |
| 1731 | MNNG |
| 1732 | modifier |
| 1733 | Molecular epidemiology |
| 1734 | Molecular pathology |
| 1735 | Molecular target |
| 1736 | Molecular target therapy |
| 1737 | Mongolian gerbil |
| 1738 | Monoclonal antibody |
| 1739 | Monocyte |
| 1740 | mPGES-1 |
| 1741 | mRNA |
| 1742 | MRP |
| 1743 | MSI |
| 1744 | mta1 |
| 1745 | MUC |
| 1746 | Mucin |
| 1747 | Multidrug resistance |
| 1748 | multinucleation |
| 1749 | Multiple myeloma |
| 1750 | Multislice CT |
| 1751 | Multistep carcinogenesis |
| 1752 | Mushroom |
| 1753 | Mutagenesis |
| 1754 | Mutant Frequency |
| 1755 | Mutation |
| 1756 | MYCN |
| 1757 | Myelodysplastic syndrome |
| 1758 | MYH |
| 1759 | Myofibroblast |
| 1760 | Myxoid chondrosarcoma |
N
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1761 | NAG-1 |
| 1762 | Nanomedicine |
| 1763 | NaPA |
| 1764 | Nasopharyngeal carcinoma |
| 1765 | Natural compounds |
| 1766 | Necl-5 |
| 1767 | Nectin |
| 1768 | Neuroblastoma |
| 1769 | Neuroendocrine |
| 1770 | neuroserpin |
| 1771 | Neutrophils |
| 1772 | NF1 |
| 1773 | NF-kB |
| 1774 | Nihon rat |
| 1775 | Nijmegen breakage syndrome |
| 1776 | Nitrosamine |
| 1777 | NK cell |
| 1778 | NK lymphoma |
| 1779 | NK4 |
| 1780 | NKT cell |
| 1781 | Nm23 |
| 1782 | N-myc |
| 1783 | NO |
| 1784 | NOG mouse |
| 1785 | Non-genotoxic carcinogen |
| 1786 | nonmyeloablative transplantation |
| 1787 | non-surgical treatment |
| 1788 | Notch |
| 1789 | Nox1 |
| 1790 | Noxa |
| 1791 | NPM-MLF1 |
| 1792 | Nrf2 |
| 1793 | NSAID |
| 1794 | Nuclear receptor |
| 1795 | Nuclear transport |
| 1796 | Nucleoside transporter |
| 1797 | Nutrient deprivation |
| 1798 | NY-ESO-1 |
O
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1799 | Obesity |
| 1800 | OGG1 |
| 1801 | OK-432 |
| 1802 | Oligodendroglioma |
| 1803 | oligonucleotide microarray |
| 1804 | Omi |
| 1805 | Oncogene |
| 1806 | Oncologist Education |
| 1807 | Oncology lecture |
| 1808 | Oncolytic virus |
| 1809 | Oral cancer |
| 1810 | Orthotopic culture |
| 1811 | osteoactivin |
| 1812 | Osteoclast |
| 1813 | Osteosarcoma |
| 1814 | Ovarian cancer |
| 1815 | ovarian surface epithelial cell |
| 1816 | Oxaliplatin |
| 1817 | Oxidative DNA damage |
| 1818 | Oxidative stress |
| 1819 | Oxygen consumption |
P
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1820 | P14ARF |
| 1821 | P16 |
| 1822 | p18 |
| 1823 | P21 |
| 1824 | P27 |
| 1825 | p38 MAPK |
| 1826 | P51 |
| 1827 | P53 |
| 1828 | P53 family genes |
| 1829 | P53 knockout mouse |
| 1830 | P53 related gene |
| 1831 | P57 |
| 1832 | p63 |
| 1833 | P73 |
| 1834 | P75NTR |
| 1835 | PA28 |
| 1836 | Paclitaxel |
| 1837 | PAI-1 |
| 1838 | pain |
| 1839 | palliative resection |
| 1840 | Pancreas |
| 1841 | Pancreatic cancer |
| 1842 | Papua New Guinea |
| 1843 | Parg |
| 1844 | Parp |
| 1845 | Patched-1 |
| 1846 | Pathology |
| 1847 | PAX family genes |
| 1848 | Paxillin |
| 1849 | PDGF |
| 1850 | PDGFRA |
| 1851 | PDK1 |
| 1852 | PDZ |
| 1853 | PEDF |
| 1854 | pediatrics |
| 1855 | Peptide |
| 1856 | Peptide vaccine |
| 1857 | Perineural invasion |
| 1858 | Periostin |
| 1859 | Peritoneal dissemination |
| 1860 | Peroxisome proliferator |
| 1861 | Personality |
| 1862 | Personalized medicine |
| 1863 | PET |
| 1864 | P-glycoprotein |
| 1865 | Phage display |
| 1866 | Pharmacogenomics |
| 1867 | Pharmacokinetics |
| 1868 | Phase I study |
| 1869 | phenotype |
| 1870 | phiC31 integrase |
| 1871 | PhIP |
| 1872 | Phosphorylation |
| 1873 | photoanalog |
| 1874 | Photodynamic therapy |
| 1875 | Physical Activity |
| 1876 | PI3-kinase |
| 1877 | Pierisin |
| 1878 | PJ-1 |
| 1879 | PKA |
| 1880 | PKC |
| 1881 | Plant |
| 1882 | Platinum drug |
| 1883 | pleura |
| 1884 | PML body |
| 1885 | podoplanin/Aggrus |
| 1886 | polo-like kinase |
| 1887 | poly-ADP-ribose |
| 1888 | Polyamine |
| 1889 | Polycomb |
| 1890 | Polyethyleneglycol |
| 1891 | Polymeric drugs |
| 1892 | Polymorphism |
| 1893 | Polyphenol |
| 1894 | Post-transcriptional regulation |
| 1895 | PP2A |
| 1896 | PPAR |
| 1897 | PPM1D |
| 1898 | Premature chromatid separation |
| 1899 | Prevention Study |
| 1900 | procyanidin B2 |
| 1901 | progenitor cells |
| 1902 | Progesterone receptor |
| 1903 | Prognosis |
| 1904 | Progression |
| 1905 | prolactin |
| 1906 | Promotion |
| 1907 | propolis |
| 1908 | Prostaglandin |
| 1909 | Prostanoid Receptor |
| 1910 | Prostate |
| 1911 | Prostate cancer |
| 1912 | prostatic small-cell carcinoma |
| 1913 | Protease |
| 1914 | Protease Nexin 1 |
| 1915 | Proteasome |
| 1916 | proteasome inhibitor |
| 1917 | Protein kinase |
| 1918 | Protein kinase inhibitor |
| 1919 | protein microarray |
| 1920 | Protein Phosphatase |
| 1921 | protein tyrosine phosphatase |
| 1922 | Protein tyrosine phosphorylation |
| 1923 | proteinase-activated receptor |
| 1924 | Protein-protein interaction |
| 1925 | proteoglycan |
| 1926 | Proteomics |
| 1927 | PSD95 |
| 1928 | PSK |
| 1929 | psychological stress |
| 1930 | psychooncology |
| 1931 | psycho-oncology |
| 1932 | PTEN |
| 1933 | PTHrP |
| 1934 | PU1 |
Q
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1935 | QOL |
| 1936 | Quantitative real time PCR |
| 1937 | quantum dot |
| 1938 | quassinoid |
| 1939 | Quiescence |
| 1940 | Quinoline |
R
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1941 | Rac |
| 1942 | Rad |
| 1943 | Radiation |
| 1944 | Radicicol analog |
| 1945 | Radioimmunotherapy |
| 1946 | Radiosensitivity |
| 1947 | Raf |
| 1948 | RANKL |
| 1949 | Rap1 |
| 1950 | Ras |
| 1951 | RAS-GAP |
| 1952 | RB |
| 1953 | RCAS1 |
| 1954 | Reactive nitrogen species |
| 1955 | Reactive oxygen species |
| 1956 | Receptor tyrosine kinase |
| 1957 | RECK |
| 1958 | Recurrence |
| 1959 | REG |
| 1960 | regeneration |
| 1961 | REGIV |
| 1962 | regulatory T cell |
| 1963 | Renal cancer cell |
| 1964 | Renal cell carcinoma |
| 1965 | replication timing |
| 1966 | Replicon |
| 1967 | representational differential analysis |
| 1968 | Ret |
| 1969 | Retinoic acid |
| 1970 | reveromycinA |
| 1971 | RFP |
| 1972 | RGD peptide |
| 1973 | rhabdomyosarcoma |
| 1974 | Rho |
| 1975 | RhoGDI |
| 1976 | Risk factor |
| 1977 | Rituximab |
| 1978 | RNA |
| 1979 | RNA interference |
| 1980 | RNA synthesis inhibitor |
| 1981 | RNA-binding protein |
| 1982 | RNAi |
| 1983 | RNF43 |
| 1984 | Runt |
| 1985 | RUNX |
| 1986 | RUNX3 |
S
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 1987 | S-1 |
| 1988 | S100 |
| 1989 | S100A4 |
| 1990 | SAGE |
| 1991 | Salivary gland tumor |
| 1992 | Salmonella typhimirium |
| 1993 | salt |
| 1994 | Sarcoma |
| 1995 | SCC antigen |
| 1996 | scFv |
| 1997 | SCID mouse |
| 1998 | Screening |
| 1999 | Second Cancer |
| 2000 | segmental duplication |
| 2001 | Selectin |
| 2002 | Semaphorin |
| 2003 | Seminoma |
| 2004 | Senescence |
| 2005 | Sensitivity test |
| 2006 | Sentinel node |
| 2007 | Septin |
| 2008 | SEREX |
| 2009 | serum markers |
| 2010 | Serum pepsinogen |
| 2011 | sFas |
| 2012 | shark |
| 2013 | Shp1 |
| 2014 | SHPS-1 |
| 2015 | Sialic acid |
| 2016 | Sialidase |
| 2017 | Sialyl Lewis a |
| 2018 | sialyltransferase |
| 2019 | Signal pathway |
| 2020 | Signal transduction |
| 2021 | Sildenafil citrate |
| 2022 | siRNA |
| 2023 | SIRT2 |
| 2024 | sister chromatid separation |
| 2025 | Skp2 |
| 2026 | SLPI |
| 2027 | Smad |
| 2028 | Small cell carcinoma |
| 2029 | small interfering RNA |
| 2030 | Small-cell lung cancer |
| 2031 | S-methylcysteine |
| 2032 | Smoking |
| 2033 | SN-38 |
| 2034 | Snail |
| 2035 | SNP |
| 2036 | SNT2 |
| 2037 | Social support |
| 2038 | SOCS |
| 2039 | SOCS-1 |
| 2040 | Soft tissue tumor |
| 2041 | Sonodynamic therapy |
| 2042 | Soy |
| 2043 | Soy isoflavone aglycon |
| 2044 | Sp1 |
| 2045 | SPA-1 |
| 2046 | Splice-site |
| 2047 | spontaneous carcinogenesis |
| 2048 | Squamous cell carcinoma |
| 2049 | Src |
| 2050 | SRC-3 |
| 2051 | SSX |
| 2052 | STAMs |
| 2053 | STAT3 |
| 2054 | Stat5 |
| 2055 | stem cell |
| 2056 | Steroid |
| 2057 | Stomach |
| 2058 | Streptococcus |
| 2059 | Stress protein |
| 2060 | Stromal |
| 2061 | Subtraction |
| 2062 | Suicide gene |
| 2063 | sulfatase |
| 2064 | Sulfotransferase |
| 2065 | SUMO-1 |
| 2066 | Suppressor gene |
| 2067 | Surfactant protein A |
| 2068 | Surgical treatment |
| 2069 | Survival |
| 2070 | Survivin |
| 2071 | Susceptibility |
| 2072 | Susceptibility gene |
| 2073 | SV40 |
| 2074 | SWI SNF complex |
| 2075 | synovial sarcoma |
| 2076 | Systems Biology |
| 2077 | SYT-SSX |
T
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2078 | T cell |
| 2079 | TAC-101 |
| 2080 | Tamoxifen |
| 2081 | Tankyrase |
| 2082 | TAOS1 |
| 2083 | Targeting |
| 2084 | TAS-103 |
| 2085 | Tat |
| 2086 | Tax |
| 2087 | Taxan derivative |
| 2088 | Taxoids |
| 2089 | TBP-2 |
| 2090 | TCF4 |
| 2091 | TEL ETV6 |
| 2092 | TEL-AML1 |
| 2093 | Telomerase |
| 2094 | Telomere |
| 2095 | Tenascin |
| 2096 | terpenoid |
| 2097 | Testicular cancer |
| 2098 | Tetramer |
| 2099 | TFPI-2 |
| 2100 | TGF-beta |
| 2101 | Th1 |
| 2102 | theanine |
| 2103 | Thioredoxin |
| 2104 | Thorotrast |
| 2105 | Threshold |
| 2106 | Thymidine phosphorylase |
| 2107 | Thymidylate synthase |
| 2108 | Thyroid |
| 2109 | Thyroid cancer |
| 2110 | tiling array |
| 2111 | TLR4 |
| 2112 | TM4SF |
| 2113 | TMS1 |
| 2114 | TNF |
| 2115 | Tob |
| 2116 | Tochu |
| 2117 | Toll-like receptor |
| 2118 | Tongue cancer |
| 2119 | Topoisomerase |
| 2120 | Toremifene |
| 2121 | Toxin |
| 2122 | TPA |
| 2123 | TRAIL |
| 2124 | Transcription |
| 2125 | Transcription coupled repair |
| 2126 | transcription factors |
| 2127 | Transfection |
| 2128 | transformation |
| 2129 | Transgenic mouse |
| 2130 | Transgenic rat |
| 2131 | translation |
| 2132 | translational research |
| 2133 | translesion DNA synthesis |
| 2134 | transplantation |
| 2135 | transporter |
| 2136 | treatment |
| 2137 | Triterpenoid |
| 2138 | tryptase |
| 2139 | TS-1 |
| 2140 | TSC |
| 2141 | TSC-22 |
| 2142 | TSLC1 |
| 2143 | Tuberous sclerosis gene |
| 2144 | tubulin |
| 2145 | Tumor antigen |
| 2146 | Tumor growth |
| 2147 | Tumor Immunity |
| 2148 | Tumor marker |
| 2149 | Tumor progression |
| 2150 | Tumor Selectivity |
| 2151 | Tumor suppressor activity |
| 2152 | Tumor suppressor gene |
| 2153 | Tumorigenicity |
| 2154 | Tumor-rejection antigen |
| 2155 | Tyrosin phospholylation |
| 2156 | Tyrosine kinase |
| 2157 | Tyrosine kinase inhibitor |
| 2158 | TZT-1027 |
U
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2159 | Ubiquitin |
| 2160 | UDP-glucuronosyltransferase |
| 2161 | Ulcerative colitis |
| 2162 | Ulinastatin |
| 2163 | ultrasound |
| 2164 | Ultraviolet irradiation |
| 2165 | undifferentiated-type gastric carcinoma |
| 2166 | UPR |
| 2167 | Uterine cancer |
| 2168 | Uterine carcinogenesis |
| 2169 | UV |
V
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2170 | Vaccine |
| 2171 | Vasculature |
| 2172 | Vasohibin |
| 2173 | Vector |
| 2174 | VEGF |
| 2175 | VEGF-C |
| 2176 | VEGF-D |
| 2177 | VEGFR2 |
| 2178 | VEGFR-3 |
| 2179 | Vesnarinone |
| 2180 | VHL |
| 2181 | Vinexin |
| 2182 | Vinorelbine |
| 2183 | Viral therapy |
| 2184 | Virus vector |
| 2185 | vitamin D receptor |
| 2186 | Vitamin D3 |
| 2187 | Vitamin K |
W
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2188 | WARTS |
| 2189 | Wee1 |
| 2190 | Werner syndrome |
| 2191 | Wilms tumor |
| 2192 | Wnt |
| 2193 | Wnt-5a |
| 2194 | WT1 |
X
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2195 | Xenograft |
| 2196 | XIAP |
| 2197 | XP |
Y
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2198 | YB-1 |
| 2199 | Yeast 2 Hybrid |
| 2200 | YY1 |
Z
0-9 - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
| CODE | Keywords |
|---|
| 2201 | ZD1839 |
| 2202 | Zinc finger |
| 2203 | Zinc-enriched yeast |
